Feb 10, 2017
They strongly also suggests that miR – is is a potential modulator CNM.. Reported by UroToday.com Editor Elspeth M. McDougall, FRCSCUroToday – the only active major urology website with original content global urology written written clinical practice involved.To get the latest urology news releases from UroToday access,miRagen Therapeutics and employees identify key role for miR – 133a as a modulator of skeletal muscle DisordermiRagen Therapeutics concentrated a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA – based therapeutics for cardiovascular and muscle disease, today announced that new preclinical data reveal an important role for miR – 133a in the maintenance of adult skeletal muscle structure and function.
Have shown that We are very pleased with the publication of these results further demonstrate the important role of excited miR – 133a in the maintenance of normal structure and function of adult skeletal muscle, said William S. Marshall, President and Chief Executive Officer of miRagen Therapeutics, treat increase These results ultimately our commitment to develop innovative microRNA-based therapeutics for patients with debilitating muscle diseases. .. the similarities in the skeletal muscle abnormalities in the miR – 133a suggest deficient mice and human patients CNM found that miR – 133a play a role in the disease, said Eric N. Chief Scientific adviser Co Co – founder of miRagen Therapeutics, the results further underscore the potential of microRNA modulation treated as a new therapeutic approach to skeletal muscle diseases. Read the rest of this entry »